Truist analyst Tobey Sommer lowered the firm’s price target on AMN Healthcare to $70 from $88 and keeps a Buy rating on the shares as part of a broader research note on Healthcare Staffing. Travel Nursing demand continues to be weak as volumes and bill rates have continued to trend lower in recent weeks, and the firm now believes it is likely Nurse & Allied revenues will again decline sequentially in Q3, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare to Hold First Quarter 2024 Earnings Conference Call on Thursday, May 9, 2024
- AMN Healthcare management to meet with Truist
- AMN Healthcare Enhances Internal Resource Pool Management for Health Systems with Vendor Neutral Technology Capabilities
- AMN Healthcare Sustainability & Social Impact Report Shows Industry-Leading Efforts
- Fly Insider: Sphere, Alaska Air among week’s notable insider trades
